1. Home
  2. SPRB vs ZBAI Comparison

SPRB vs ZBAI Comparison

Compare SPRB & ZBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRB
  • ZBAI
  • Stock Information
  • Founded
  • SPRB 2014
  • ZBAI 2015
  • Country
  • SPRB United States
  • ZBAI United States
  • Employees
  • SPRB N/A
  • ZBAI N/A
  • Industry
  • SPRB Medicinal Chemicals and Botanical Products
  • ZBAI Professional Services
  • Sector
  • SPRB Health Care
  • ZBAI Consumer Discretionary
  • Exchange
  • SPRB Nasdaq
  • ZBAI Nasdaq
  • Market Cap
  • SPRB 15.7M
  • ZBAI 16.8M
  • IPO Year
  • SPRB 2020
  • ZBAI N/A
  • Fundamental
  • Price
  • SPRB $0.42
  • ZBAI $1.08
  • Analyst Decision
  • SPRB Hold
  • ZBAI
  • Analyst Count
  • SPRB 7
  • ZBAI 0
  • Target Price
  • SPRB $2.17
  • ZBAI N/A
  • AVG Volume (30 Days)
  • SPRB 417.1K
  • ZBAI 1.6M
  • Earning Date
  • SPRB 03-12-2025
  • ZBAI 03-04-2025
  • Dividend Yield
  • SPRB N/A
  • ZBAI N/A
  • EPS Growth
  • SPRB N/A
  • ZBAI N/A
  • EPS
  • SPRB N/A
  • ZBAI N/A
  • Revenue
  • SPRB $7,101,000.00
  • ZBAI $495,000.00
  • Revenue This Year
  • SPRB N/A
  • ZBAI N/A
  • Revenue Next Year
  • SPRB N/A
  • ZBAI N/A
  • P/E Ratio
  • SPRB N/A
  • ZBAI N/A
  • Revenue Growth
  • SPRB N/A
  • ZBAI N/A
  • 52 Week Low
  • SPRB $0.34
  • ZBAI $0.58
  • 52 Week High
  • SPRB $5.95
  • ZBAI $2.50
  • Technical
  • Relative Strength Index (RSI)
  • SPRB 58.94
  • ZBAI N/A
  • Support Level
  • SPRB $0.38
  • ZBAI N/A
  • Resistance Level
  • SPRB $0.42
  • ZBAI N/A
  • Average True Range (ATR)
  • SPRB 0.03
  • ZBAI 0.00
  • MACD
  • SPRB 0.00
  • ZBAI 0.00
  • Stochastic Oscillator
  • SPRB 69.77
  • ZBAI 0.00

About SPRB Spruce Biosciences Inc.

Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).

About ZBAI ATIF Holdings Limited Ordinary Shares

ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.

Share on Social Networks: